Acute myeloid leukemia (AML) does not have numbered stages the way breast or colon cancer does. Because it starts in the bone marrow and is already circulating in the blood at diagnosis, AML is instead “staged” by three things: its subtype under the WHO or ICC classification, its genetic risk group, and its disease phase (newly diagnosed, in remission, or relapsed). This detailed guide walks through each layer and explains how they shape treatment and outlook.
AML is a heterogeneous group of clonal disorders in which immature myeloid cells, called myeloblasts, multiply without maturing. They crowd out normal blood production and lead to bone marrow failure. For a broader comparison with other leukemias, see our overview of leukemia stages.
Why AML Has No TNM Stage
The TNM system describes tumor size, lymph node spread, and distant metastasis. None of those concepts fits a cancer that begins in the marrow and is present throughout the body from day one. A patient with AML is never “stage 1” or “stage 4” in the solid-tumor sense.
What predicts outcome in AML is biology rather than anatomy. The chromosomal and gene changes inside the leukemic cells, together with the patient’s age and fitness, tell us far more than any measure of where the disease has spread.
The Old FAB Subtypes
Older textbooks describe the French-American-British (FAB) system, which sorted AML into subtypes M0 to M7 by how the cells looked under the microscope. M3, for example, is acute promyelocytic leukemia, and M7 is acute megakaryoblastic leukemia. The FAB labels are still heard on the wards, but they have been replaced in modern practice by genetically based classifications.
Classification: WHO and ICC Categories
Current diagnosis uses the World Health Organization (WHO) classification and the closely related International Consensus Classification (ICC). Both group AML primarily by its defining genetic abnormality, then by features such as myelodysplasia-related changes or prior therapy.
| Category | Examples | Clinical meaning |
|---|---|---|
| AML with defining genetic abnormalities | t(8;21), inv(16), t(15;17) PML::RARA, NPM1 mutation | Often identify favorable-risk or specifically treatable disease |
| AML, myelodysplasia-related | Complex karyotype, certain gene mutations such as ASXL1 or TP53-associated changes | Generally adverse; more common in older adults |
| AML after cytotoxic therapy | Prior chemotherapy or radiation | Usually harder to treat |
| AML defined by differentiation | Cases without a defining genetic lesion | Described by lineage and maturation |
Traditionally, a diagnosis of AML required at least 20% blasts in the blood or marrow. The newer classifications lower or remove that threshold when a defining genetic abnormality is present, because the genetics, not the blast count, drive behavior.
Genetic Risk Groups: The Functional “Stage”
The closest thing AML has to a stage is its European LeukemiaNet (ELN) risk category. The ELN guidelines place patients into favorable, intermediate, or adverse risk based on cytogenetics and molecular results. This grouping guides the most important decision after induction: whether to recommend a stem cell transplant in first remission.
| ELN risk group | Typical genetic findings | General implication |
|---|---|---|
| Favorable | t(8;21), inv(16), NPM1 mutation without FLT3-ITD, in-frame bZIP CEBPA mutation | Good response to chemotherapy; transplant often deferred |
| Intermediate | t(9;11), findings not classed as favorable or adverse | Transplant considered case by case |
| Adverse | Complex or monosomal karyotype, TP53 mutation, -5/del(5q), -7, inv(3) | Higher relapse risk; transplant usually recommended if fit |
Recurrent mutations in FLT3, NPM1, IDH1/IDH2, and CEBPA are now tested routinely, both for risk and because several have matching targeted drugs. Outcomes by group are discussed in more depth in our article on AML survival rates.
Disease Phases Across the Treatment Course
In day-to-day practice, clinicians describe where a patient is in the course of the illness. These phases act as a practical staging vocabulary.
- Newly diagnosed (active) disease: blasts are filling the marrow and usually the blood, and the patient often has cytopenias.
- Complete remission (CR): fewer than 5% marrow blasts, no circulating blasts, no extramedullary disease, and recovery of counts (neutrophils at least 1.0 x 10^9/L and platelets at least 100 x 10^9/L).
- Measurable residual disease (MRD): leukemia detectable only by sensitive flow cytometry or molecular testing while the patient is in morphological remission. MRD positivity signals higher relapse risk.
- Relapsed disease: return of blasts in the marrow or blood, or disease outside the marrow, after a remission.
- Refractory disease: failure to achieve remission after induction therapy.
How AML Is Diagnosed and Risk-Stratified
The symptoms of AML come from bone marrow suppression and tissue infiltration: fatigue from anemia, infections from neutropenia, and bruising or bleeding from low platelets. Gum hypertrophy, skin deposits (leukemia cutis), and hepatosplenomegaly may be seen, particularly in monocytic subtypes. Understanding the normal composition and function of bone marrow helps explain why every cell line is affected.
Workup starts with a full blood count and film, then a bone marrow aspiration and biopsy. The sample goes for morphology, flow cytometry to confirm myeloid lineage, conventional karyotyping, FISH, and a next-generation sequencing panel. Flow cytometry is also how AML is distinguished from other hematologic malignancies such as ALL.
Coagulation studies are urgent, because acute promyelocytic leukemia can present with life-threatening disseminated intravascular coagulation. Suspected APL is treated as a medical emergency, with all-trans retinoic acid started before genetic confirmation.
How Risk and Phase Guide Treatment
Treatment runs in two main steps. Induction aims for complete remission; in fit patients this has classically been cytarabine plus an anthracycline (the “7+3” regimen), with a FLT3 inhibitor added for FLT3-mutated disease. Consolidation then aims to eradicate residual cells, using further chemotherapy or allogeneic stem cell transplantation.
Older or less fit patients are often treated with a hypomethylating agent combined with venetoclax, which is better tolerated than intensive induction. IDH1 and IDH2 inhibitors are options when those mutations are present. For adverse-risk disease, or intermediate risk with persistent MRD, allogeneic transplant offers the best chance of cure but carries risks including graft-versus-host disease.
Key Takeaways
- AML has no TNM stage; its “stage” is really its classification, genetic risk group, and disease phase.
- The WHO and ICC systems classify AML mainly by defining genetic abnormalities.
- ELN favorable, intermediate, and adverse risk categories guide transplant decisions.
- Complete remission, MRD status, relapse, and refractory disease describe where a patient stands during treatment.
- Full marrow workup with cytogenetics and molecular testing is essential before treatment is finalized. Our guide to hematological disorders gives wider context, and the leukemia guide covers related topics.
Frequently Asked Questions
Is there a stage 4 AML?
No. AML is not staged with numbers, so there is no stage 4 AML. When people use that phrase they usually mean high-risk, relapsed, or refractory disease, which should be described in those terms instead.
What determines prognosis in AML if not stage?
The main factors are the genetic findings (ELN risk group), the patient’s age and overall fitness, whether the leukemia arose from a prior blood disorder or earlier therapy, and how deeply it responds to treatment, including MRD status.
What does MRD-negative mean?
It means sensitive tests such as flow cytometry or molecular PCR cannot detect leukemia cells in the marrow. MRD negativity after treatment is associated with a lower risk of relapse, although it does not guarantee cure.
Why does AML genetic testing take longer than the initial diagnosis?
Morphology and flow cytometry can confirm AML within a day or two, but karyotyping and sequencing panels take longer. Treatment decisions, such as adding a FLT3 inhibitor, often wait for these results unless the patient needs urgent therapy.
